Nintedanib Stada (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR 1‑3, FGFR 1‑3, and PDGFR α/β—thereby reducing fibroblast activity, new blood‑vessel formation, and tumor cell proliferation, which helps slow fibrosis and tumor progression.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions exactly.

Safety data for nintedanib in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Nintedanib is a multi‑kinase inhibitor targeting VEGFR, FGFR, and PDGFR pathways, offering a broader spectrum of activity than agents that inhibit a single receptor. Compared with pirfenidone, another antifibrotic, nintedanib has a distinct side‑effect profile and is often chosen based on patient tolerance and comorbidities.

Nintedanib Stada should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not store in a bathroom or near heat sources to maintain product stability.

The medication is taken orally, usually with food to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include liver injury, severe bleeding, arterial thromboembolic events, gastrointestinal perforations, and hypertension. Patients should be monitored regularly for signs of these events, and therapy should be discontinued if severe adverse reactions occur.

Nintedanib is contraindicated in patients with severe hepatic impairment, uncontrolled cardiovascular disease, active bleeding disorders, or known hypersensitivity to nintedanib or any of its excipients. It should also be avoided in pregnant women unless the potential benefit outweighs the risk.